natgillin/translations-raw huggingface dataset:
Other events that may occur in patients, who require this type of treatment, include those that are related to the condition you are having treated, such as rapid or irregular heartbeat, low blood pressure, shock or cardiac arrest. 
Drugi događaji koji mogu nastupiti u bolesnika koji zahtijevaju ovu vrstu terapije uključuju one koji su povezani sa stanjima koja se liječe, kao što su brz ili nepravilan rad srca, niski krvni tlak, šok ili zastoj rada srca.
When administered alone, eptifibatide has no measurable effect on prothrombin time (PT) or activated partial thromboplastin time (aPTT). 
Kad se daje sam, eptifibatid nema mjerljiv učinak na protrombinsko vrijeme (PV) ili na aktivirano parcijalno tromboplastinsko vrijeme (aPTT).
Specifically, no patients experienced an intracranial bleed. 
Specifično, niti jedan bolesnik nije razvio intrakranijalno krvarenje.
Eptifibatide p-Value 
Eptifibatid p-vrijednost
No formal pharmacokinetic interaction studies have been conducted. 
Formalna istraživanja farmakokinetičkih interakcija nisu provođena.
0.034a a: Pearson's chi-square test of difference between placebo and eptifibatide. 
0,034a a: Paersonov hi-kvadrat razlike između placeba i eptifibatida.
- reduced blood flow to the brain. 
− smanjeni dotok krvi u mozak.
- Eptifibatide Accord is not intended for use in children or adolescents less than 18 years of age. 
− Eptifibatid Accord nije namijenjen za primjenu u djece ili adolescenata mlađih od 18 godina.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. 
• Periodička izvješća o neškodljivosti Zahtjevi za podnošenje periodičkih izvješća o neškodljivosti za ovaj lijek definirani su u referentnom popisu datuma EU (EURD popis) predviđenim člankom 107(c) stavkom 7 Direktive 2001/83/EZ i svim sljedećim nadopunama objavljenim na europskom internetskom portalu za lijekove.
Monitor these patients closely with regard to bleeding. 
Takve bolesnike treba pažljivo nadzirati radi krvarenja.
It is usually given with aspirin and unfractionated heparin. 
Obično se primjenjuje zajedno s aspirinom i nefrakcioniranim heparinom.
Animal studies are insufficient with respect to effects on pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). 
Ispitivanja na životinjama su nedostatna za konačan zaključak u pogledu trudnoće, embriofetalnog razvoja, poroda i postnatalnog razvoja (vidjeti dio 5.3).
This product is for hospital use only. 
Ovaj lijek se primjenjuje samo u bolnicama.
This means that it helps to prevent blood clots from forming. 
To znači da pomaže u sprječavanju nastanka krvnih ugrušaka.
For this diagnosis, within 24 hours after the index PCI procedure, there had to be at least two CK-MB values ≥ 3 x the upper limit of normal; thus, validation by the CEC was not required. 
Za ovu dijagnozu u 24 sata od PCI postupka najmanje dvije CK-MB vrijednosti morale su biti ≥ 3 x iznad gornje granice normale; stoga validacija od strane Povjerenstva za kliničke događaje nije bila potrebna.
It should be administered by specialist physicians experienced in the management of acute coronary syndromes. 
Trebaju ga primjenjivati liječnici specijalisti s iskustvom u liječenju akutnog koronarnog sindroma.
The decision to use platelet transfusions should be based upon clinical judgment on an individual basis. 
Odluku o transfuziji trombocita treba temeljiti na kliničkoj prosudbi u svakom pojedinom slučaju.
Patients could be enrolled only if they had experienced cardiac ischemia at rest (≥ 10 minutes) within the previous 24 hours and had: 
Bolesnici su mogli biti uključeni samo ako su u prethodna 24 sata imali srčanu ishemiju u mirovanju (≥ 10 minuta) i jedno od sljedećeg:
Arterial sheaths may be removed when coagulation has returned to normal (e.g. when activated clotting time (ACT) is less than 180 seconds (usually 2-6 hours after discontinuation of heparin). 
Arterijske uvodnice mogu se odstraniti kad se koagulacija vrati u normalu (npr. kad je aktivirano vrijeme zgrušavanja (ACT) manje od 180 sekundi (obično 2-6 sati nakon prestanka davanja heparina).
Potentially, an overdose of eptifibatide could result in bleeding. 
Prevelika doza eptifibatida potencijalno može izazvati krvarenje.
The vast majority of patients received acetylsalicylic acid (75-325 mg once daily). 
Velika većina bolesnika primala je acetilsalicilatnu kiselinu (75-325 mg jednom na dan).
Prolongation of bleeding time 
Produljenje vremena krvarenja
− if you are allergic to eptifibatide or any of the other ingredients of this medicine (listed in section 
− ako ste alergični na eptifibatid ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
The clinical relevance of such enzymatic MIs is still controversial. 
Klinički značaj tih enzimskih infarkta miokarda još uvijek je kontroverzan.
PURSUIT was conducted at a time when the standard of care of managing acute coronary syndromes was different from that of present times in terms of thienopyridine use and the routine use of intracoronary stents. 
PURSUIT ispitivanje je provođeno u vrijeme kada je standard liječenja akutnih koronarnih sindroma bio različit od današnjeg u pogledu upotrebe tienopiridina i rutinske ugradnje intrakoronarnih stentova.
If you have kidney disease, the infusion dose may be reduced to 1 microgram/kg/minute. 
Ako bolujete od neke bolesti bubrega, infuzijska doza može se smanjiti na 1 mikrogram/kg/minuti.
Eptifibatide Accord should not be used during pregnancy unless clearly necessary. 
Eptifibatid Accord ne treba primjenjivati tijekom trudnoće osim u slučaju jasne potrebe.
There was no indication of severe adverse reactions associated with administration of accidental large bolus doses, rapid infusion reported as overdose or large cumulative doses. 
Ne postoje naznake teških nuspojava povezanih sa slučajnim davanjem velikih bolus doza, brzim infuzijama prijavljenim kao predoziranje ili visokim kumulativnim dozama.
Reproduction studies in animal species where eptifibatide shows a similar pharmacologic activity as in humans are not available. 
Nisu provedene reproduktivne studije na životinjama gdje bi eptifibatid pokazao sličnu farmakološku aktivnost kao u ljudi.
Thus, although eptifibatide can be dialysed, the need for dialysis is unlikely. 
Stoga, iako se eptifibatid može dijalizirati, nije vjerojatno da će biti potrebna dijaliza.
• either ST-segment changes: ST depression > 0.5 mm of less than 30 minutes or persistent ST elevation > 0.5 mm not requiring reperfusion therapy or thrombolytic agents, T-wave inversion (> 1 mm), 
• promjene ST-segmenta: depresiju ST segmenta > 0,5 mm u trajanju manjem od 30 minuta ili trajnu ST elevaciju > 0,5 mm koja ne zahtijeva reperfuzijsku terapiju ili trombolitike, inverziju T-vala (> 1 mm)
The component MI could be defined as asymptomatic with enzymatic elevation of CK-MB or new Q wave. 
Komponenta IM može se definirati kao asimptomatska s povišenjem enzima CK-MB ili novonastalim Q-zupcem.
ESPRIT trial 
Ispitivanje ESPRIT
Consequently the use of Eptifibatide Accord is not recommended in these circumstances (see section 4.5). 
Stoga se u takvim okolnostima ne preporuča primjena Eptifibatid Accorda (vidjeti dio 4.5).
Warnings and precautions 
Upozorenja i mjere opreza:
Tell your doctor if you are pregnant, think you might be pregnant or are planning to have a baby. 
Ako ste trudni, mislite da biste mogli biti trudni ili planirate imati dijete, obratite se svom liječniku.
- if you have been treated with another medicine of the same type as Eptifibatide Accord. 
− ako ste bili liječeni nekim drugim lijekom istog djelovanja kao Eptifibatid Accord.
Eptifibatide Accord is not compatible with furosemide. 
Eptifibatid Accord nije kompatibilan s furosemidom.
< 1/1000); very rare (< 1/10,000); not known (cannot be estimated from available data). 
1/1000), vrlo rijetko (< 1/10000); nepoznato (učestalost se ne može procijeniti iz dostupnih podataka).
The primary endpoint of the study was the occurrence of death from any cause or new myocardial infarction (MI) (evaluated by a blinded Clinical Events Committee) within 30 days of randomisation. 
Primarna mjera ishoda studije bila je pojava smrti zbog bilo kojeg uzroka ili novog infarkta miokarda (IM) (prema evaluaciji zaslijepljenog Povjerenstva za kliničke događaje) unutar 30 dana od randomizacije.
No unexpected toxic effects for an agent with this pharmacologic profile were observed and findings were predictive of clinical experience, with bleeding effects being the principal adverse event. 
Nisu zamijećeni neočekivani toksični učinci za tvar s takvim farmakološkim profilom i na osnovu rezultata moglo se predvidjeti kliničko iskustvo, s krvarenjem kao glavnom nuspojavom.
Shock, hypotension, phlebitis. 
Često šok, hipotenzija, flebitis
The reduction in the incidence of endpoint events in patients receiving eptifibatide appeared early during treatment (within the first 72-96 hours) and this reduction was maintained through 6 months, without any significant effect on mortality. 
Smanjenje incidencije događaja mjere ishoda u bolesnika koji su primali eptifibatid dogodilo se u ranoj fazi liječenja (u prvih 72-96 sati) i to se smanjenje održalo tijekom 6 mjeseci, bez značajnog utjecaja na mortalitet.
Women, the elderly, patients with low body weight or with moderate renal impairment (creatinine clearance > 30 - < 50 ml/min) may have an increased risk of bleeding. 
Žene, stariji, osobe male tjelesne težine ili s umjerenim oštećenjem bubrega (klirens kreatinina ≥ 30 do ≤ 50 ml/min) mogu imati povećani rizik od krvarenja.
An increased risk of bleeding may also be observed in patients who receive early administration of eptifibatide (e.g. upon diagnosis) compared to receiving it immediately prior to PCI, as seen in the Early ACS trial. 
Povećani rizik od krvarenja se može vidjeti i u bolesnika koji rano prime eptifibatid (npr. odmah po postavljenoj dijagnozi), u odnosu na primjenu neposredno prije PCI, kao što je zamijećeno u ‘Early ACS' ispitivanju.
There is no experience with eptifibatide and low molecular weight heparins. 
Nema iskustava s primjenom eptifibatida i heparina niske molekulske težine.
During treatment with eptifibatide there is a significant increase in bleeding rates, especially in the femoral artery area, where the catheter sheath is introduced. 
Tijekom liječenja eptifibatidom dolazi do značajnog povećanja stope krvarenja, osobito u području femoralne arterije, gdje se postavlja uvodnica katetera.
Note that causality has not been determined for all adverse reactions. 
Treba napomenuti da uzročno-posljedična veza nije utvrđena za sve nuspojave.
As demonstrated in clinical trials, the incidence of thrombocytopenia was low, and similar in patients treated with eptifibatide or placebo. 
Kao što je pokazano u kliničkim ispitivanjima, incidencija trombocitopenije bila je niska i slična u bolesnika koji su bili liječeni eptifibatidom ili placebom.
These are absolute reporting frequencies without taking into account placebo rates. 
To su apsolutne frekvencije učestalosti bez uzimanja u obzir stope pri primjeni placeba.
Your doctor will weigh up the benefit to you against the risk to your baby of using Eptifibatide Accord while you are pregnant. 
Vaš će liječnik procijeniti korist primjene Eptifibatid Accorda za Vas i rizik za Vaš plod tijekom trudnoće.
Changes during eptifibatide treatment result from its known pharmacological action, i.e., inhibition of platelet aggregation. 
Promjene do kojih dolazi za vrijeme liječenja eptifibatidom posljedica su njegovog poznatog farmakološkog djelovanja, tj. inhibicije agregacije trombocita.
Other potential bleeding sites such as central and peripheral nervous system and retroperitoneal sites, must be carefully considered too. 
Treba voditi računa i o ostalim potencijalnim mjestima krvarenja poput središnjeg i perifernog živčanog sustava i retroperitoneuma.
Patients were to undergo an invasive strategy for further management after receiving study drug for 12 to 96 hours. 
Bolesnici su trebali biti podvrgnuti invazivnom liječenju nakon primanja ispitivanog lijeka tijekom 12 do 96 sati.
A total of 1,250 patients underwent PCI within 72 hours after randomisation, in which case they received intravenous unfractionated heparin to maintain an activated clotting time (ACT) of 300-350 seconds. 
Ukupno je 1250 bolesnika podvrgnuto PCI unutar 72 sata nakon randomizacije, i tada su primili nefrakcionirani heparin intravenski kako bi se održalo aktivno vrijeme zgrušavanja (ACT) od 300-350 sekundi.
In the same population, plasma elimination half-life is approximately 2.5 hours, plasma clearance 55 to 80 ml/kg/hr and volume of distribution of approximately 185 to 260 ml/kg. 
U istoj populaciji, poluvrijeme eliminacije iz plazme je približno 2,5 sata, klirens plazme je 55 do 80 ml/kg/h i volumen distribucije je približno 185 do 260 ml/kg.
What Eptifibatide Accord is and what it is used for What you need to know before you are given Eptifibatide Accord How to use Eptifibatide Accord 
Što je Eptifibatid Accord i za što se koristi Što morate znati prije nego počnete primati Eptifibatid Accord Kako primjenjivati Eptifibatid Accord
In healthy subjects, renal excretion accounted for approximately 50 % of total body clearance; approximately 50 % of the amount cleared is excreted unchanged. 
U zdravih ispitanika, izlučivanje putem bubrega je odgovorno za oko 50 % ukupnog tjelesnog klirensa; približno 50 % od te količine se izlučuje nepromijenjeno.
It is used in adults with manifestation of severe coronary insufficiency defined as spontaneous and recent chest pain with electrocardiographic abnormalities or biological changes. 
Koristi se u bolesnika s teškom koronarnom insuficijencijom, koja se definira kao spontana i nedavna bol u prsima s elektrokardiografskim abnormalnostima ili biološkim promjenama.
How to store Eptifibatide Accord Contents of the pack and other information 
Kako čuvati Eptifibatid Accord Sadržaj pakiranja i druge informacije
Results on the primary endpoint were principally attributed to the occurrence of myocardial infarction. 
Rezultati primarne mjere ishoda prvenstveno su bili pripisani nastupu infarkta miokarda.
There are no adequate data from the use of eptifibatide in pregnant women. 
Nema dovoljno podataka o primjeni eptifibatida u trudnica.
At the recommended therapeutic dose, as administered in the PURSUIT trial involving nearly 11,000 patients, bleeding was the most common complication encountered during eptifibatide therapy. 
U preporučenim terapijskim dozama primijenjenim u PURSUIT ispitivanju koje je uključivalo gotovo 11 000 bolesnika, krvarenje je bila najčešća komplikacija tijekom terapije eptifibatidom.
In PURSUIT, bleeding and non-bleeding events were collected from hospital discharge to the 30 day visit. 
U PURSUIT ispitivanju prikupljani su podaci za krvarenja i događaje nevezane uz krvarenja nakon otpusta iz bolnice do kontrolne posjete 30. dana.
Cardiac arrest, congestive heart failure, atrial fibrillation, hypotension, and shock, which are commonly reported events from the PURSUIT trial, were events related to the underlying disease. 
Kardijalni arest, kongestivno zatajenje srca, fibrilacija atrija, hipotenzija i šok koji se ubrajaju u česte nuspojave iz PURSUIT ispitivanja, bile su događaji vezani uz osnovnu bolest.
Unlike the approved posology in the EU, all patients in this trial were administered a double bolus before the infusion (see section 5.1). 
Za razliku od odobrenog načina doziranja lijeka u EU, svi su bolesnici u tom ispitivanju primali dvostruku bolus dozu prije infuzije (vidjeti dio 5.1).
Please refer to the Normosol R Summary of Product Characteristics for details on its composition. 
Molimo pogledati Sažetak opisa svojstava lijeka Normosol R otopine za detaljni sastav iste.
GUSTO severe/life threatening bleeding was uncommon and comparable in both treatment groups (0.8 %). 
Prema GUSTO kriterijima, jako/životno ugrožavajuće krvarenje je bilo manje često i usporedivo u pojavnosti za obje ispitivane skupine (0,8 %).
The 180/1.3 arm was stopped after an interim analysis, as prespecified in the protocol, when the two active-treatment arms appeared to have a similar incidence of bleeding. 
Krak 180/1,3 prekinut je nakon interim analize predviđene planom ispitivanja, kad se ustanovilo da dva aktivno liječena kraka imaju sličnu incidenciju krvarenja.
To avoid the possibility of interactions with other medicines please tell your doctor or hospital pharmacist or nurse if you are taking or have recently taken or might take any other medicines, including medicines obtained without a prescription. 
Obavijestite svog liječnika ili bolničkog ljekarnika ako uzimate ili ste nedavno uzeli ili biste mogli uzeti bilo koje druge lijekove, uključujući i one koje ste nabavili bez recepta.
Of the patients in PURSUIT, 13 % were managed with PCI during eptifibatide infusion, of whom approximately 50 % received intracoronary stents; 87 % were managed medically (without PCI during eptifibatide infusion). 
Od bolesnika uključenih u PURSUIT, 13 % je imalo PCI tijekom infuzije eptifibatida, od kojih je u oko 50 % ugrađen intrakoronarni stent; 87 % je primalo samo lijekove (bez PCI tijekom infuzije eptifibatida).
In the PURSUIT trial, there were 9 patients who received bolus and/or infusion doses more than double the recommended dose, or who were identified by the investigator as having received an overdose. 
U ispitivanju PURSUIT, 9 je bolesnika primilo doze bolusa i/ili infuzije koje su bile više nego dvostruko veće od onih preporučenih, ili za koje je ispitivač ustanovio da su primili preveliku dozu.
If serious bleeding occurs that is not controllable with pressure, the Eptifibatide Accord infusion should be stopped immediately and any unfractionated heparin that is given concomitantly. 
Dođe li do ozbiljnog krvarenja koje se ne da zaustaviti pritiskom, valja odmah prekinuti infuziju Eptifibatid Accorda i nefrakcioniranog heparina koji se istodobno primjenjuje.
Eptifibatide, a synthetic cyclic heptapeptide containing six amino acids, including one cysteine amide and one mercaptopropionyl (desamino cysteinyl) residue, is an inhibitor of platelet aggregation and belongs to the class of RGD (arginine-glycine-aspartate)-mimetics. 
Eptifibatid, sintetski ciklički heptapeptid koji sadrži šest aminokiselina, uključujući jedan cisteinamid i jednu reziduu merkaptopropionila (dezaminocisteinil), je inhibitor agregacije trombocita i pripada klasi RGD (arginin-glicin-aspartat)-mimetika.
What Eptifibatide Accord is and what it is used for 2. 
Što je Eptifibatid Accord i za što se koristi 2.
- skin rash (such as hives). 
− osip kože (kao što je koprivnjača).
In patients undergoing PCI, measure the ACT also. 
Ako se bolesnik podvrgava PCI, treba mjeriti i ACT.
When followed by a 2.0 microgram/kg/min continuous infusion, this regimen produces a > 80 % inhibition of ADP-induced ex vivo platelet aggregation, at physiologic calcium concentrations, in more than 80 % of patients. 
Kad se nastavno primjeni 2,0 mikrograma/kg/min kontinuiranom infuzijom, ovaj režim dovodi do > 80 % inhibicije ex vivo ADP-om inducirane agregacije trombocita, pri fiziološkim koncentracijama kalcija, u više od 80 % bolesnika.
Eptifibatide Accord is intended for use with acetylsalicylic acid and unfractionated heparin. 
Eptifibatid Accord je namijenjen za primjenu zajedno s acetilsalicilatnom kiselinom i nefrakcioniranim heparinom.
In ESPRIT, bleeding events were reported at 48 hours, and non-bleeding events were reported at 30 days. 
U ESPRIT ispitivanju krvarenja su procjenjivana nakon 48 sati, a događaji nevezani uz krvarenja 30. dana.
Teratology studies have been performed by continuous intravenous infusion of eptifibatide in pregnant rats at total daily doses of up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis) and in pregnant rabbits at total daily doses of up to 36 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis). 
Provedena su teratološka ispitivanja kontinuiranom intravenskom infuzijom eptifibatida nosećim ženkama štakora u ukupnim dnevnim dozama do 72 mg/kg/dan (oko 4 puta većoj od maksimalne preporučene dnevne doze za ljude, mjereno prema površini tijela) i kunića u ukupnoj dnevnoj dozi do 36 mg/kg/dan (isto oko 4 puta većoj od maksimalne preporučene dnevne doze za ljude, mjereno prema površini tijela).
Use in patients with more severe renal impairment is contraindicated (see section 4.3). 
Primjena u bolesnika s težim oštećenjem bubrega je kontraindicirana (vidjeti dio 4.3).
Thrombocytopenia and Immunogencity related to GP IIb/IIIa inhibitors 
Trombocitopenija i imunogeničnost vezana uz GP IIb/IIIa inhibitore
The majority of adverse reactions experienced by patients treated with eptifibatide were generally related to bleeding or to cardiovascular events that occur frequently in this patient population. 
Većina nuspojava u bolesnika liječenih eptifibatidom obično je vezana uz krvarenja ili kardiovaskularne pojave koje su česte u toj populaciji bolesnika.
During treatment with eptifibatide in this study, minor bleeding was a very common complication (> 1/10, or 13.1 % for eptifibatide versus 7.6 % for placebo). 
Tijekom liječenja eptifibatidom u ovom ispitivanju manje krvarenje je bilo vrlo česta komplikacija (>1/10 ili 13,1 % uz eptifibatid u odnosu na 7,6 % uz placebo).
Haemoglobin, haematocrit, and platelet count are to be monitored as well within 6 hours after start of therapy and at least once daily thereafter while on therapy (or more often if there is evidence of a marked decrease). 
Hemoglobin, hematokrit i broj trombocita treba također provjeriti i unutar 6 sati od početka liječenja, a nakon toga najmanje jednom dnevno tijekom samog liječenja (ili češće ako postoje dokazi značajnog pada).
The infusion was continued until hospital discharge, until the time of coronary artery bypass grafting (CABG) or for up to 72 hours, whichever occurred first. 
Infuzija se nastavila do otpusta iz bolnice, do početka operacije ugradnje premosnice koronarne arterije (CABG) ili do najviše 72 sata, ovisno o tome što se dogodilo prije.
Pharmacotherapeutic group: Antithrombotic agent (platelet aggregation inhibitors excl. heparin), ATC code: B01AC16 
Farmakoterapijska skupina: Antitrombotici (inhibitori agregacije trombocita izuzev heparina), ATK oznaka: B01AC16
Thrombocytopenia occurring after first exposure to a GPIIb/IIIa inhibitor may be explained by the fact that antibodies are naturally present in some normal individuals. 
Trombocitopenija koja se javlja nakon prvog izlaganja inhibitoru GPIIb/IIIa može biti objašnjena činjenicom da se takva antitijela prirodno mogu naći u pojedinih, inače zdravih osoba.
Not relevant, as Eptifibatide Accord is intended for use only in hospitalised patients. 
Nije značajno, budući da je Eptifibatid Accord namijenjen liječenju isključivo hospitaliziranih bolesnika.
Since either repeat exposure with any GP IIb/IIIa ligand-mimetic agent (like abciximab or eptifibatide) or first-time exposure to a GP IIb/IIIa inhibitor may be associated with immune-mediated thrombocytopenic responses, monitoring is required, i.e. platelet counts should be monitored prior to treatment, within 6 hours of administration, and at least once daily thereafter while on therapy and immediately at clinical signs of unexpected bleeding tendency. 
Obzirom da ponovna izloženost bilo kojem GP IIb/IIIa ligand-mimetiku (poput abciksimaba ili eptifibatida) ili prva izloženost GP IIb/IIIa inhibitoru može biti povezano s imunološki posredovanim odgovorom u vidu trombocitopenije, praćenje je neophodno, tj. broj trombocita potrebno je provjeriti prije početka liječenja, unutar 6 sati od početka primjene, a nakon toga najmanje jednom dnevno tijekom samog liječenja ili i odmah ako nastupe klinički znakovi neočekivanog krvarenja.
Other medicines and Eptifibatide Accord 
Drugi lijekovi i Eptifibatid Accord
- if you have had a brain tumour or a condition that affects the blood vessels around the brain. 
− ako ste imali tumor na mozgu ili stanje koje utječe na krvne žile oko mozga.